
Deferoxamine Injection
Form: Injection
Strength: 500 mg/mL
Reference Brands: Desferal(US)
Category: Blood Disorder
Deferoxamine injection, marketed as Desferal, is approved in the US by the FDA and in the EU via EMA for treating iron overload and poisoning. Regulatory approval requires a detailed dossier including clinical safety, efficacy, manufacturing, and pharmacovigilance data. In the US, submission to the FDA involves comprehensive review, while in the EU, EMA guidelines ensure quality and safety standards are met. For expert guidance on dossier development, regulatory pathways, and successful market access, visit PharmaTradz. Ensuring compliance with regional regulations is essential for the safe and effective use of deferoxamine injection worldwide, supporting patients with iron overload conditions.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Anti-Inhibitor Coagulant Complex (AICC) Lyophilized Powder
Strength: 500 units, 1000 units, and 2500 units
Form: Lyophilized Powder (Reconstituted for IV infusion)
Reference Brands: FEIBA(US)
View Details Get EnquiryProthrombin Complex Concentrate (PCC) injection
Strength: 250 IU to 300 IU
Form: Injection
Reference Brands: Kcentra (4-factor PCC), Bebulin VH (3-factor PCC)(US)
View Details Get EnquiryMesna Injection
Strength: 100 mg/mL
Form: Injection
Reference Brands: Mesnex(US)
View Details Get EnquiryLeucovorin tablets/Capsule
Strength: 15 mg, 50 mg
Form: Tablet/Capsules
Reference Brands: Folvite(US & EU)
View Details Get Enquiry